Skip to main content
Fig. 6 | Breast Cancer Research

Fig. 6

From: First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models

Fig. 6

Immunohistochemistry demonstrating in vivo cell cycle arrest through p21 and enhanced apoptotic rate when combining ALRN-6924 with paclitaxel. a Scatter plots of in vivo immunohistochemistry (IHC) H-score p21 activity in both MCF-7 and ZR-75-1 xenografts. Mean ± SD is shown. b IHC images and scatter plots of in vivo percentages and density of TUNEL-positive tumor cells after treatment with vehicle, ALRN-6924, paclitaxel, or combination of both in both MCF-7 and ZR-75-1 xenografts. Mean ± SD is shown

Back to article page